

Supplemental FIGURE 1. Best PSA Response following focal therapy (EBRT) to ¹⁸F-rhPSMA-7 PET.



Supplemental FIGURE 2. True positive intraspinal metastasis



Sagittal fused PET/CT (A), and CT (B) revealed focal ¹⁸F-rhPSMA-7 uptake at a soft tissue lesion located at intraspinal sacrum level (arrow), representing intraspinal metastasis measured about 2.9 cm in long axis diameter. He received external beam radiation at this region up to a total dose of 37.5 Gy, VMAT technique supplemented by androgendeprivation therapy, from August to September 2018. PSA was decreased from 1.44 ng/ml to 0.6 ng/ml after treatment. The follow up sagittal fused PET/CT (C), and CT (D) showed no significant change in size of aforementioned lesion, measured about 2.8 cm. This case was recorded as true positive according to significant PSA decreased (-58%) after targeted therapy.

Supplemental TABLE 1. Baseline characteristics of patients with PSA response following focal therapy (N = 25)

Age, median (range), years 71 (59-82) Other prior therapy Local salvage therapy 1 (4) ADT 1(4) Multiple 2 (8) Other 1 (4) Not available / no prior treatment 20 (80) Time between surgery and PSMA PET, median (range), 2.3 (0-15) years 2.25 <2.25 12 (48) ≥2.25 13 (52) Primary T stage <t3< td=""> 10 (40) ≥T3 14 (56) Not available 1 (4) Pathologic regional LN staging (pN) pN0 14 (56) pN1 6 (24) pNx 5 (20) Gleason Score <8 17 (68) ≥8 3 (12) Not available 5 (20) PSA, median (range), months 5.98 (4-12) dtPSA*, median (range), months 7.89 (2-33) <6.8 3 (12) ≥6.8 4 (16) Not available 18 (72) PSA nadir after prostatectomy**, medi</t3<>	Characteristic	No. (%)
Local salvage therapy ADT ADT (4) ADT (4) Multiple (2 (8) Other (1 (4) Not available / no prior treatment (20 (80) Time between surgery and PSMA PET, median (range), years <2.2.5 2.2.5 12 (48) ≥2.25 Primary T stage <t3 (12)="" (16)="" (20)="" (24)="" (40)="" (56)="" (68)="" (pn)="" (range),="" 10="" 14="" 17="" 3="" 4="" 5="" 6="" <0.1="" <6.8="" <8="" after="" available="" gleason="" ln="" median="" ml="" months="" nadir="" ng="" not="" pathologic="" pn0="" pn1="" pnx="" prostatectomy**,="" psa="" psa,="" regional="" score="" staging="" td="" €="" ≥0.1="" ≥0.1<="" ≥6.8="" ≥8="" ≥t3=""><td>Age, median (range), years</td><td>71 (59-82)</td></t3>	Age, median (range), years	71 (59-82)
ADT 1(4) Multiple 2 (8) Other 1 (4) Not available / no prior treatment 20 (80) Time between surgery and PSMA PET, median (range), 2.3 (0-15) years <2.25 12 (48) ≥2.25 13 (52) Primary T stage <t3 (0-19)="" (12)="" (16)="" (2-33)="" (20)="" (24)="" (4)="" (4-12)="" (40)="" (56)="" (68)="" (72)="" (pn)="" (range),="" 0.03="" 1="" 10="" 14="" 17="" 18="" 3="" 4="" 5="" 5.98="" 6="" 7.89="" <0.1="" <6.8="" <8="" after="" available="" dtpsa*,="" gleason="" ln="" median="" ml="" months="" nadir="" ng="" not="" pathologic="" pn0="" pn1="" pnx="" prostatectomy**,="" psa="" psa,="" regional="" score="" staging="" td="" ≥0.1="" ≥0.1<="" ≥6.8="" ≥8="" ≥t3=""><td>Other prior therapy</td><td></td></t3>	Other prior therapy	
Multiple 2 (8) Other 1 (4) Not available / no prior treatment 20 (80) Time between surgery and PSMA PET, median (range), 2.3 (0-15) years	Local salvage therapy	1 (4)
Other 1 (4) Not available / no prior treatment 20 (80) Time between surgery and PSMA PET, median (range), 2.3 (0-15) years	ADT	1(4)
Not available / no prior treatment 20 (80) Time between surgery and PSMA PET, median (range), 2.3 (0-15) years <2.25 12 (48) ≥2.25 13 (52) Primary T stage <t3 (0-19)="" (12)="" (16)="" (16)<="" (2-33)="" (20)="" (24)="" (4)="" (4-12)="" (40)="" (56)="" (68)="" (72)="" (pn)="" (range),="" 0.03="" 1="" 10="" 14="" 17="" 18="" 3="" 4="" 5="" 5.98="" 6="" 7.89="" <0.1="" <6.8="" <8="" after="" available="" dtpsa*,="" gleason="" ln="" median="" ml="" months="" nadir="" ng="" not="" pathologic="" pn0="" pn1="" pnx="" prostatectomy**,="" psa="" psa,="" regional="" score="" staging="" td="" ≥0.1="" ≥6.8="" ≥8="" ≥t3=""><td>Multiple</td><td>2 (8)</td></t3>	Multiple	2 (8)
Time between surgery and PSMA PET, median (range), 2.3 (0-15) years 2.2.25 12 (48) ≥2.25 13 (52) Primary T stage <t3< td=""> 10 (40) ≥T3 14 (56) Not available 1 (4) PAthologic regional LN staging (pN) 14 (56) pN0 14 (56) pN1 6 (24) pNx 5 (20) Gleason Score 48 ≥8 3 (12) Not available 5 (20) PSA, median (range), months 5.98 (4-12) dtPSA*, median (range), months 7.89 (2-33) <6.8</t3<>	Other	1 (4)
years <2.25 12 (48) ≥2.25 13 (52) Primary T stage <t3 (0-19)="" (12)="" (16)="" (16)<="" (2-33)="" (20)="" (24)="" (4)="" (4-12)="" (40)="" (56)="" (68)="" (72)="" (pn)="" (range),="" 0.03="" 1="" 10="" 14="" 17="" 18="" 3="" 4="" 5="" 5,98="" 6="" 7.89="" <0.1="" <6.8="" <8="" after="" available="" dtpsa*,="" gleason="" ln="" median="" ml="" months="" nadir="" ng="" not="" pathologic="" pn0="" pn1="" pnx="" prostatectomy**,="" psa="" psa,="" regional="" score="" staging="" td="" ≥0.1="" ≥6.8="" ≥8="" ≥t3=""><td>Not available / no prior treatment</td><td>20 (80)</td></t3>	Not available / no prior treatment	20 (80)
<2.25	Time between surgery and PSMA PET, median (range),	2.3 (0-15)
≥2.25 Primary T stage <t3 (0-19)="" (12)="" (16)="" (16)<="" (2-33)="" (20)="" (24)="" (4)="" (4-12)="" (40)="" (56)="" (68)="" (72)="" (pn)="" (range),="" 0.03="" 1="" 10="" 14="" 17="" 18="" 3="" 4="" 5="" 5.98="" 6="" 7.89="" <0.1="" <6.8="" <8="" after="" available="" dtpsa*,="" gleason="" ln="" median="" ml="" months="" nadir="" ng="" not="" pathologic="" pn0="" pn1="" pnx="" prostatectomy**,="" psa="" psa,="" regional="" score="" staging="" td="" ≥0.1="" ≥6.8="" ≥8="" ≥t3=""><td>years</td><td></td></t3>	years	
Primary T stage <t3 (0-19)="" (12)="" (16)="" (16)<="" (2-33)="" (20)="" (24)="" (4)="" (4-12)="" (40)="" (56)="" (68)="" (72)="" (pn)="" (range),="" 0.03="" 1="" 10="" 14="" 17="" 18="" 3="" 4="" 5="" 5.98="" 6="" 7.89="" <0.1="" <6.8="" <8="" after="" available="" dtpsa*,="" gleason="" ln="" median="" ml="" months="" nadir="" ng="" not="" pathologic="" pn0="" pn1="" pnx="" prostatectomy**,="" psa="" psa,="" regional="" score="" staging="" td="" ≥0.1="" ≥6.8="" ≥8="" ≥t3=""><td><2.25</td><td>12 (48)</td></t3>	<2.25	12 (48)
<t3< td=""> 10 (40) ≥T3 14 (56) Not available 1 (4) Pathologic regional LN staging (pN) pN0 14 (56) pN1 6 (24) pNx 5 (20) Gleason Score <8</t3<>	≥2.25	13 (52)
≥T3 Not available Pathologic regional LN staging (pN) pN0 pN1 6 (24) pNx 5 (20) Gleason Score <8 17 (68) ≥8 17 (68) ≥8 Not available 5 (20) PSA, median (range), months 4.12) dtPSA*, median (range), months <6.8 ≥6.8 3 (12) Not available 18 (72) PSA nadir after prostatectomy**, median (range), ng/ml <0.1 €0.1 €0.1 4 (16)	Primary T stage	
Not available 1 (4) Pathologic regional LN staging (pN) pN0 14 (56) pN1 6 (24) pNx 5 (20) Gleason Score <8	<t3< td=""><td>10 (40)</td></t3<>	10 (40)
Pathologic regional LN staging (pN) pN0	≥T3	14 (56)
pN0 14 (56) pN1 6 (24) pNx 5 (20) Gleason Score <8 17 (68) ≥8 3 (12) Not available 5 (20) PSA, median (range), months 5.98 (4-12) dtPSA*, median (range), months 7.89 (2-33) <6.8 3 (12) ≥6.8 4 (16) Not available 18 (72) PSA nadir after prostatectomy**, median (range), ng/ml 0.03 (0-19) <0.1 6 (24) ≥0.1 4 (16)	Not available	1 (4)
pN1 6 (24) pNx 5 (20) Gleason Score <8 17 (68) ≥8 3 (12) Not available 5 (20) PSA, median (range), months 5.98 (4-12) dtPSA*, median (range), months 7.89 (2-33) <6.8 3 (12) ≥6.8 4 (16) Not available 18 (72) PSA nadir after prostatectomy**, median (range), ng/ml 0.03 (0-19) <0.1 6 (24) ≥0.1 4 (16)	Pathologic regional LN staging (pN)	
pNx 5 (20) Gleason Score <8 17 (68) ≥8 3 (12) Not available 5 (20) PSA, median (range), months 5.98 (4-12) dtPSA*, median (range), months 7.89 (2-33) <6.8 3 (12) ≥6.8 4 (16) Not available 18 (72) PSA nadir after prostatectomy**, median (range), ng/ml 0.03 (0-19) <0.1 6 (24) ≥0.1 4 (16)	pN0	14 (56)
Gleason Score <8	pN1	6 (24)
<8	pNx	5 (20)
≥8 3 (12) Not available 5 (20) PSA, median (range), months 5.98 (4-12) dtPSA*, median (range), months 7.89 (2-33) <6.8 3 (12) ≥6.8 4 (16) Not available 18 (72) PSA nadir after prostatectomy**, median (range), ng/ml 0.03 (0-19) <0.1 6 (24) ≥0.1 4 (16)	Gleason Score	
Not available 5 (20) PSA, median (range), months 5.98 (4-12) dtPSA*, median (range), months 7.89 (2-33) <6.8	<8	17 (68)
PSA, median (range), months 5.98 (4-12) dtPSA*, median (range), months 7.89 (2-33) <6.8 3 (12) ≥6.8 4 (16) Not available 18 (72) PSA nadir after prostatectomy**, median (range), ng/ml <0.1 ≤0.1 6 (24) ≥0.1 4 (16)	≥8	3 (12)
dtPSA*, median (range), months 7.89 (2-33) <6.8	Not available	5 (20)
<6.8	PSA, median (range), months	5.98 (4-12)
≥6.8 4 (16) Not available 18 (72) PSA nadir after prostatectomy**, median (range), ng/ml 0.03 (0-19) <0.1 6 (24) ≥0.1 4 (16)	dtPSA*, median (range), months	7.89 (2-33)
Not available 18 (72) PSA nadir after prostatectomy**, median (range), ng/ml 0.03 (0-19) <0.1	<6.8	3 (12)
PSA nadir after prostatectomy**, median (range), ng/ml 0.03 (0-19) <0.1	≥6.8	4 (16)
<0.1 6 (24) ≥0.1 4 (16)	Not available	18 (72)
≥0.1 4 (16)	PSA nadir after prostatectomy**, median (range), ng/ml	0.03 (0-19)
· · ·	<0.1	6 (24)
Not available 15 (60)	≥0.1	4 (16)
	Not available	15 (60)

Supplemental TABLE 2. Lesions validated as false positive by follow-up imaging per-region

Location	Per-region (N=11)	%	Criteria of false positive†
Prostate bed	2	18	In 3-12 months follow up; all PSMA- positive lesion which do not meet the
Pelvic lymph node	6	55	following criteria; a) size decrease >30% with systemic / focal therapy, b) size
Extrapelvic lymph nodes/ Visceral organs	2	18	increase >20% with/without systemic / focal therapy, and c) minimum size change of 3 mm is required Short axis diameter was used for lymph node lesion - Long axis diameter was used for lesions at prostate bed and visceral organs
Bone	1	9	Negative in additional bone scan or MRI

[†]According to UCLA/UCSF criteria follow up imaging / PSA response (Fendler et al. JAMA Oncol. 2019;5:856-863).

Supplemental TABLE 3. Lesions validated as false positive by follow-up imaging per-patient

Location	Per-patient	%
	(N=10)	
Prostate bed only	1	10
Pelvic lymph node only	5	50
Extrapelvic lymph nodes/ Visceral	2	20
organs only		
Bone only	1	10
Prostate bed, and pelvic lymph	1	10
node		

Supplemental TABLE 4. Individual false positive lesions

				follow up study, days (months)
Prostate bed				
Soft tissue after RPE	Systemic treatment (ADT)	Decreased size: 18%; 7 mm (38mm → 31 mm)	size decrease <30% after systemic therapy	263 (9)
Soft tissue after RPE	Systemic treatment (ADT)	Decreased size: 12%; 2mm (17mm → 15 mm)	size decrease <30% after systemic therapy, and minimum size change < 3 mm	426 (14)
Pelvic lymph node			-	
Pelvic lymph node	Systemic treatment (ADT)	Decreased size: 41%; 1.5 mm (3.7 mm → 2.2. mm)	minimum size change < 3 mm	426 (14)
Pelvic lymph node	No treatment	No size change: 0%; 0 mm (3.5 mm → 3.5 mm)	minimum size change < 3 mm	105 (4)
Pelvic lymph node	No treatment	Increased size: 5%; 0.2 mm (4.1 mm → 4.3 mm)	size increase <20% without therapy, and minimum size change <3 mm	185 (6)
Pelvic lymph node	No treatment	Increased size: 4%; 0.2 mm (4.7 mm → 4.9 mm)	size increase <20% without therapy, and minimum size change <3 mm	159 (5) 202 (7)
	Soft tissue after RPE Pelvic lymph node Pelvic lymph node Pelvic lymph node Pelvic lymph node	Soft tissue after RPE Systemic treatment (ADT) Soft tissue after Systemic treatment (ADT) Pelvic lymph node Pelvic lymph node Pelvic lymph node Systemic treatment (ADT) Pelvic lymph node No treatment Pelvic lymph node No treatment Pelvic lymph node No treatment Pelvic lymph node No treatment	Soft tissue after RPE Systemic treatment (ADT) Soft tissue after RPE Systemic treatment (38mm → 31 mm) Soft tissue after RPE Systemic treatment (ADT) Pelvic lymph node Pelvic lymph node Pelvic lymph node Pelvic lymph node No treatment (ADT) Pelvic lymph node No No size change: 0%; 0 mm (3.5 mm → 3.5 mm) Pelvic lymph node No Increased size: 5%; 0.2 mm (4.1 mm → 4.3 mm) Pelvic lymph node Pelvic lymph node No Increased size: 5%; 0.2 mm (4.1 mm → 4.3 mm) Pelvic lymph node No Increased size: 4%; 0.2 mm (4.7 mm → 4.9 mm)	Soft tissue after RPE Systemic treatment (ADT) Systemic treatment (ADT) Pelvic lymph node No Systemic treatment (ADT) No size change < 3 mm No size change < 3 mm No size change < 3 mm Pelvic lymph node No Treatment No Increased size: change < 3 mm Pelvic lymph node No Increased size: size increase Size increase

THE JOURNAL OF NUCLEAR MEDICINE • Vol. 62 • No. 7 • July 2021

Chantadisai et al.

		treatment (ADT)	0%; 0 (13 mm → 13 mm)	change <3 mm	
R1184	Pelvic lymph node	No treatment	Decreased size: 6%; 0.5 mm (8.0 mm → 7.5 mm)	size increase <20% without therapy, and minimum size change < 3 mm	155 (5)
	Bone lesions				
R985	Bone	Systemic treatment (ADT)	Negative in additional MRI	Negative in additional bone scan or MRI	102 (3)
	Extrapelvic lymph nodes / visceral lesions				
R478	Retroperitoneal lymph node	No treatment	No size change: 0%; 0 mm (18 mm → 18 mm)	size increase <20% without therapy, and minimum size change < 3 mm	103 (3)
R524	Lung	No treatment	Increased size: 14%; 1 mm (7 mm → 8 mm)	size increase <20% without therapy, and minimum size change < 3 mm	117 (4)

Supplemental TABLE 5. Non-evaluable lesions on per-patient and per-region basis

Location	Per-patient	%	Per-region	%
	(N=7)		(N=8)	
Prostate bed	1	14	2	25
Pelvic lymph node	1	14	1	13
Visceral organs	0	0	0	0
Bone	4	58	5	62
>1 regions	1	14	0	0

Supplemental TABLE 6. Individual non-evaluable lesions

Patient number	Lesion type	Treatment after PET	Explanation	Time to follow/up study, days (months)
	Prostate bed			
R464	Soft tissue after RPE	Systemic treatment (ADT)	No reliably measurable lesion; lesion is adjacent to rectum	81 (3)
R990	Soft tissue after RPE	No treatment	No reliably measurable lesion; lesion is adjacent to rectum	195 (7)
	Pelvic lymph node			
R156	Pelvic lymph node	Systemic treatment (ADT)	No reliably measurable lesion; lesion is adjacent to iliac vein with similar density in CT	236 (8)
	Bone			
R344	Bone	EBRT (left 3 rd rib, and pelvic region) with ADT	PSMA-positive lesion without corresponding sclerosis in baseline and follow up CT	364 (12)
R158	Bone	Systemic treatment (ADT)	PSMA-positive lesion without corresponding sclerosis in baseline and follow up CT	329 (11)
R464	Bone	Systemic treatment (ADT)	PSMA-positive lesion without corresponding sclerosis in baseline and follow up CT	81 (3)
R582	Bone	Systemic treatment (ADT)	PSMA-positive lesion without corresponding sclerosis in baseline and follow up CT	238 (8)
R969	Bone	No treatment	PSMA-positive lesion without corresponding sclerosis in baseline and follow up CT	152 (5)